Prudential Financial Inc Jounce Therapeutics, Inc. Transaction History

Prudential Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $97,006 - $265,727	-34,645 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$6.01 - $8.54 $85,943 - $122,121	14,300 Added 70.29%	34,645 $235,000
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $167,120 - $226,588	-23,505 Reduced 53.6%	20,345 $170,000
Q3 2020 Nov 16, 2020	SELL	$4.58 - $10.95 $6,824 - $16,315	-1,490 Reduced 3.29%	43,850 $358,000
Q2 2020 Aug 12, 2020	SELL	$4.17 - $7.58 $105,471 - $191,720	-25,293 Reduced 35.81%	45,340 $312,000
Q1 2020 May 12, 2020	SELL	$2.91 - $8.7 $82,079 - $245,392	-28,206 Reduced 28.54%	70,633 $335,000
Q4 2019 Feb 11, 2020	SELL	$2.81 - $9.21 $94,028 - $308,185	-33,462 Reduced 25.29%	98,839 $862,000
Q3 2019 Nov 13, 2019	SELL	$3.33 - $4.93 $392,716 - $581,409	-117,933 Reduced 47.13%	132,301 $440,000
Q2 2019 Aug 08, 2019	BUY	$4.3 - $6.73 $180,647 - $282,734	42,011 Added 20.18%	250,234 $0
Q1 2019 May 15, 2019	BUY	$3.43 - $6.87 $584,019 - $1.17 Million	170,268 Added 448.6%	208,223 $0
Q4 2018 Feb 07, 2019	BUY	$2.69 - $6.71 $102,098 - $254,678	37,955 New	37,955 $127,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.